This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dikov, M. M. Articles by Carbone, D. P. Search for Related Content PubMed PubMed Citation Articles by Dikov, M. M. Articles by Carbone, D. P.

Vascular Endothelial Growth Factor Effects on Nuclear Factor-B Activation in Hematopoietic Progenitor Cells¹

The Vanderbilt Cancer Center and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838 [M. M. D., T. O., T. T., K. T., T. S., B. E., Y. A., S. N., T. D., D. P. C.], and Department of Pathology and Cardinal Bernardin Cancer Center, Loyola University of Chicago, Maywood, Illinois 60153, [P. C., D. I. G.]

Vascular endothelial growth factor (VEGF) inhibits of the activation of transcription factor nuclear factor-B (NF-B) in hematopoietic progenitor cells (HPCs), and this is associated with alterations in the development of multiple lineages of hematopoietic cells and defective immune induction in tumor-bearing animals. Antibodies to VEGF have been shown to abrogate this effect. The mechanism by which VEGF antagonizes the induction of NF-B was investigated in this study. Using supershift electrophoretic mobility shift analysis, we found that although tumor necrosis factor (TNF-) induced the nuclear translocation and DNA binding of p65-containing complexes, VEGF alone induced nuclear translocation and DNA binding of the complexes containing RelB. These results were confirmed by immunofluorescence confocal microscopy. VEGF effectively blocked TNF--induced NF-B activation in HPCs from RelB^-/- mice, however, similar to the effect observed in HPCs obtained from RelB^+/- and RelB^+/+ mice. This suggests that RelB is not required for VEGF to inhibit NF-B activation. However, although TNF- induced rapid activation of IB kinase (IKK) as expected, this activity was substantially reduced in the presence of VEGF. This decreased IKK activation correlated with the inhibition of IB phosphorylation and degradation of IB and IB in HPCs. VEGF alone, however, did not have any effect on phosphorylation of IB or degradation of IB and other inhibitory molecules IBß, IB, or Bcl-3. SU5416, a potent inhibitor of the VEGF receptor 1 (VEGFR1) and VEGFR2 receptor tyrosine kinases, did not abolish the inhibitory effect of VEGF, indicating that the VEGF effect is mediated by a mechanism unrelated to VEGFR1 or VEGFR2 tyrosine kinase activity. Thus, VEGF appears to inhibit TNF--induced NF-B activation by VEGFR kinase-independent inhibition of IKK. Therapeutic strategies aimed at overcoming VEGF-mediated defects in immune induction in tumor-bearing hosts will need to target this kinase-independent pathway.

This article has been cited by other articles:

				Y. Huang, X. Chen, M. M. Dikov, S. V. Novitskiy, C. A. Mosse, L. Yang, and D. P. Carbone Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF Blood, July 15, 2007; 110(2): 624 - 631. [Abstract] [Full Text] [PDF]

				R. Yang, Z. Cai, Y. Zhang, W. H. Yutzy IV, K. F. Roby, and R. B.S. Roden CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells. Cancer Res., July 1, 2006; 66(13): 6807 - 6815. [Abstract] [Full Text] [PDF]

				B. Larrivee, I. Pollet, and A. Karsan Activation of Vascular Endothelial Growth Factor Receptor-2 in Bone Marrow Leads to Accumulation of Myeloid Cells: Role of Granulocyte-Macrophage Colony-Stimulating Factor J. Immunol., September 1, 2005; 175(5): 3015 - 3024. [Abstract] [Full Text] [PDF]

				M. M. Dikov, J. E. Ohm, N. Ray, E. E. Tchekneva, J. Burlison, D. Moghanaki, S. Nadaf, and D. P. Carbone Differential Roles of Vascular Endothelial Growth Factor Receptors 1 and 2 in Dendritic Cell Differentiation J. Immunol., January 1, 2005; 174(1): 215 - 222. [Abstract] [Full Text] [PDF]

				A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn Vascular Endothelial Growth Factor and Angiogenesis Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580. [Abstract] [Full Text] [PDF]

				Z. F. Yang, R. T. Poon, Y. Luo, C. K. Cheung, D. W. Ho, C. M. Lo, and S. T. Fan Up-Regulation of Vascular Endothelial Growth Factor (VEGF) in Small-for-Size Liver Grafts Enhances Macrophage Activities through VEGF Receptor 2-Dependent Pathway J. Immunol., August 15, 2004; 173(4): 2507 - 2515. [Abstract] [Full Text] [PDF]

				P. Monti, B. E. Leone, A. Zerbi, G. Balzano, S. Cainarca, V. Sordi, M. Pontillo, A. Mercalli, V. Di Carlo, P. Allavena, et al. Tumor-Derived MUC1 Mucins Interact with Differentiating Monocytes and Induce IL-10highIL-12low Regulatory Dendritic Cell J. Immunol., June 15, 2004; 172(12): 7341 - 7349. [Abstract] [Full Text] [PDF]

				Y. Wang, J. Chang, Y.-C. Li, Y.-S. Li, J. Y.-J. Shyy, and S. Chien Shear stress and VEGF activate IKK via the Flk-1/Cbl/Akt signaling pathway Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H685 - H692. [Abstract] [Full Text] [PDF]

				Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer J. Immunol., January 1, 2004; 172(1): 464 - 474. [Abstract] [Full Text] [PDF]

				P. Cheng, Y. Nefedova, L. Miele, B. A. Osborne, and D. Gabrilovich Notch signaling is necessary but not sufficient for differentiation of dendritic cells Blood, December 1, 2003; 102(12): 3980 - 3988. [Abstract] [Full Text] [PDF]

				D. K. Biswas, S.-C. Dai, A. Cruz, B. Weiser, E. Graner, and A. B. Pardee The nuclear factor kappa B (NF-kappa B): A potential therapeutic target for estrogen receptor negative breast cancers PNAS, August 17, 2001; (2001) 151257998. [Abstract] [Full Text] [PDF]

				D. K. Biswas, S.-C. Dai, A. Cruz, B. Weiser, E. Graner, and A. B. Pardee The nuclear factor kappa B (NF-kappa B): A potential therapeutic target for estrogen receptor negative breast cancers PNAS, August 28, 2001; 98(18): 10386 - 10391. [Abstract] [Full Text] [PDF]